Xing Liying, Liu Shuang, Tian Yuanmeng, Yan Han, Jing Li, Chen Kangjing, Yan Fei, Li Yingqiu, Lv Jianfeng, Sun Yingxian
Department of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, PR China; Disease Control and Prevention of Liaoning Province, Shenyang, Liaoning, PR China.
Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
J Stroke Cerebrovasc Dis. 2019 May;28(5):1400-1408. doi: 10.1016/j.jstrokecerebrovasdis.2019.02.009. Epub 2019 Mar 11.
Limited data are available on the impact of fasting plasma glucose (FPG) on outcomes in nondiabetic acute ischemic stroke patients.
The prospective, multi-center, and observational study was performed at 8 hospitals in the Liaoning Province between 2015-2016, sought to elucidate the relationship between FPG and the 6-month functional outcomes in nondiabetic acute ischemic stroke patients. The primary effect measure was the adjusted odds ratio for a shift in the direction of unfavorable outcome on the modified Rankin Scale (mRS) score at 6 months, estimated with an ordinal logistic regression, and adjusted for common prognostic factors. Finally, we employed a restricted cubic spline function of linear model to characterize concentration-response (C-R) relationships between FPG and outcomes.
A total of 1260 consecutive patients were enrolled, 48.9% of patients had FPG levels >6.1mmol/L. A total of 282 (22.4%) patients achieved an unfavorable neurologic outcome. Patients achieving an unfavorable neurologic outcome had significantly higher levels of FPG than those achieving a favorable neurologic outcome (6.47mmol/L versus 7.02 mmol/L). FPG was significantly related to an unfavorable neurologic outcome in nondiabetic acute ischemic stroke patients. The C-R curve showed a nonlinear relation between FPG and 6-month mRS with the nadir at 5.9mmol/L. Moreover, the likelihood of unfavorable outcome increased by 8.5% for each 1mmol/L increase in FPG.
Early identification and prompt hyperglycemia management should be considered to improve the functional outcomes during the early poststroke stage.
关于空腹血糖(FPG)对非糖尿病急性缺血性卒中患者预后影响的数据有限。
2015年至2016年期间,在辽宁省的8家医院进行了一项前瞻性、多中心观察性研究,旨在阐明非糖尿病急性缺血性卒中患者FPG与6个月功能预后之间的关系。主要效应指标是通过有序逻辑回归估计的6个月时改良Rankin量表(mRS)评分向不良预后方向转变的调整优势比,并对常见预后因素进行调整。最后,我们采用线性模型的受限立方样条函数来描述FPG与预后之间的浓度-反应(C-R)关系。
共纳入1260例连续患者,48.9%的患者FPG水平>6.1mmol/L。共有282例(22.4%)患者出现不良神经功能预后。出现不良神经功能预后的患者FPG水平显著高于出现良好神经功能预后的患者(6.47mmol/L对7.02mmol/L)。FPG与非糖尿病急性缺血性卒中患者的不良神经功能预后显著相关。C-R曲线显示FPG与6个月mRS之间呈非线性关系,最低点为5.9mmol/L。此外,FPG每升高1mmol/L,不良预后的可能性增加8.5%。
应考虑早期识别并及时管理高血糖,以改善卒中后早期的功能预后。